September 25, 2018
Further to Mylan's announcement in May 2018 (see the previous story here) regarding the supply constraints on EpiPen® 0.3mg and 0.15mg Adrenaline Auto-Injector in the UK. Mylan has released the following update dated 14th September 2018:
'Our manufacturing partner Meridian Medical Technologies, a Pfizer company, continues to experience interruptions in the production of EpiPen® 0.3mg and EpiPen® Jr 0.15mg Adrenaline Auto-Injectors.
We continue to maintain a stock management process for the distribution of EpiPen® 0.3mg and EpiPen® Jr 0.15mg Adrenaline Auto-Injectors. Pharmacies are allocated product on a prescription-only basis and can place orders for up to a maximum of two EpiPen® 0.3mg and two EpiPen® Jr 0.15mg Adrenaline Auto-Injectors per prescription.'
EpiPen® Jr 0.15mg Adrenaline Auto-Injector
This issue is now also affecting EpiPen Jr 0.15mg Adrenaline Auto-Injector in the UK. Mylan recently informed us that EpiPen Jr 0.15mg Adrenaline Auto-Injectors are now out of stock and unlikely to be available until the end of September.
Due to the supply situation with EpiPen Jr 0.15mg, supplies of both Jext and Emerade 0.15mg adrenaline auto-injectors have been rapidly depleted and are currently unavailable.
Additional supplies of Jext and Emerade are expected by the end of September. Please note supplies will be limited and the situation is likely to be constrained until the Mylan supply situation has resolved.
EpiPen® 0.3mg Adrenaline Auto-Injector
Pfizer recently made available to Mylan a limited volume of EpiPen 0.3mg Auto-Injectors that will expire in February 2019. This supply is not subject to the current prescription validation process. Pharmacies wishing to order EpiPen® 0.3mg Adrenaline Auto-Injectors with an expiry date of February 2019 should refer to the "Instructions for Pharmacists" section of Mylans statement which can be found here.
There are two alternative adrenaline auto-injector products available in the UK, Emerade and Jext. Supplies of both presentations are currently available but may be limited due to the ongoing Epipen supply issues.
Mylan say that 'Pfizer is working hard to increase production and anticipates supply will stabilise in the fourth quarter of 2018; however, it is important to note that currently supply from Pfizer continues to vary and, as such, may not always be available for pharmacies to order.
Distribution of EpiPen® 0.3mg and EpiPen® Jr 0.15mg Auto-Injectors in the UK is being carefully monitored, in coordination with our UK distribution partner, Alliance Healthcare, to help manage product availability on an ongoing basis until a steady supply resumes. We will continue to proactively and diligently update pharmacies, healthcare professionals and patient advocacy groups across the country regarding any changes in stock availability.'
Patients with concerns over supply should visit their GP who may wish to prescribe an alternative brand if required, for example, Emerade® or Jext®.
Additional advice and information can be found on the Anaphylaxis campaign website here.
For more information please see the attached statement from Mylan
To read more Press Release articles, click here.